Fosun Pharma subsidiary gains approval for Luvometinib and Fovinaciclib

Shanghai Fosun Pharmaceutical (HKEX: 02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from the National Medical Products Administration (NMPA) for Luvometinib Tablets. This approval covers the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms, as well as pediatric patients two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN).